


# Quan-Plex™ EGFR Patient-Like ctDNA Reference Standard

Recent advances in Next-Generation Sequencing (NGS) and digital PCR (dPCR) have enabled the development of quantitative assays that can detect low amounts of mutant DNA. The high sensitivity of these new technologies, often down to 1 in 1000 mutant alleles (i.e. 0.1 %) or lower, has enabled non-invasive cancer profiling through what have become known as “liquid biopsies”, or the detection of cancer-associated somatic variants from circulating tumor DNA (ctDNA) in blood specimens. Examples of applications where ctDNA testing has shown promise are: blood screening for early cancer detection, therapy selection, routine monitoring of cancer to assess minimal residual disease, and resistance monitoring during therapy.




The Quan-Plex™ EGFR ctDNA Reference Standard is a highly-characterized, quantitative multiplex quality control that allows researchers to develop their own assays, and assess limits of detection (LODs) for 10 non-small cell lung cancer (NSCLC) solid tumor mutations. This panel can also be used to monitor the quality of their NGS or dPCR oncology-based workflow for routine quality assessment. The standards have been engineered to mimic the fragmentation profile of nucleosomal ctDNA (~166 bp) as observed in patient samples.



### Key Feature & Benefits:

- Highly-characterized ctDNA mimetic reference standard
- 166 bp average length mimics true ctDNA samples
- 9 cancer-associated mutations in EGFR
- Available at 0%, 0.1%, 1.0% and 5.0% mutant allele frequencies
- Cancer cell lines provides a true biologically-relevant control
- Digital PCR and NGS-verified



### Digital PCR Verified Mutations\*:

Gene	Nucleotide Change	Amino Acid Change	Cosmic ID	Variant Type
EGFR	c. 2155G>A	p. G719S	6252	Substitution
EGFR	c. 2573T>G	p. L858R	6224	Substitution
EGFR	c. 2369C>T	p. T790M	6240	Substitution
EGFR	c.2582T>A	p. L861Q	6213	Substitution
EGFR	c. 2236_2250del15	p. E746_A750del	6225	Deletion
EGFR	c. 2303G>T	p. S768I	6241	Substitution
EGFR**	c. 2307_2308insGCCAGCGTG	p. V769_D770insASV	12376	Insertion
EGFR	c. 2389T>A	p. C797S	6493937	Substitution
EGFR	c.2281G>T	p. D761Y	21984	Substitution
EGFR	c. 2125G>A	p. E709K	12988	Substitution

\*For dPCR verified mutations please refer to lot specific certificate of conformity (CoC) available on the product page at [www.accuref.com](http://www.accuref.com)

\*\* This mutation is detected by NGS and not quantified by digital PCR

### Technical Information:

Genes Covered	EGFR
dPCR Verified Mutations	9
Allelic Frequency Range	0%, 0.1%, 1% and 5%
Fragment Size	150-166 bp

## Ordering:

Catalog # ARF-1006CT    Quan-Plex™ EGFR Patient-like ctDNA Panel

Catalog # ARF-1006CTP    Quan-Plex™ EGFR Patient-like ctDNA Panel - In Synthetic Plasma

## Format:

Unit Size                    1 Panel

Quantity                    4 vials of 7.5µl ctDNA mimetic (300ng/vial for ARF-1006CT), or 4 vials of 500µl each of ctDNA mimetic in synthetic plasma (300ng/vial for ARF-1006CTP)

Concentration              40 ng/µl (ARF-1006CT); 0.6 ng/µl (ARF-1006CTP)

Intended Use                For routine NGS performance monitoring and assess limit of detection of ctDNA with NGS or dPCR assays

## General:

Storage                      -20°C (long term) 2 years Exp Date

Freeze/Thaw                No more than 3 freeze/thaw cycles

Shipping                     4°C (gel packs)

Cell Line Background      RKO/HCT116

Buffer                        Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.0 (ARF-1006CT)  
Synthetic Plasma pH 8.5 (ARF-1006CTP)

Regulatory                 For Research Use Only. Not intended for human or animal diagnostics or therapeutic use.

## Quality Control:

Genotype                    Sanger sequencing of locus specific PCR (cell line)

Quality                      BioAnalyzer™ DNA1000 Chip and Next-generation sequencing: AmpliSeq™ Hotspot Cancer Panel v2 for Illumina

Quantification             Qubit 4.0™ Fluorometer  
Mutation allele frequency: digital PCR  
\*\*Detected but not quantified with NGS. Allele frequency for this variant will be observed only with NGS.

Manufacturing             ISO 9001:2015 and ISO 13485:2016 certified

Cosmic ID	Nucleotide Change	Amino Acid Change	Target/Total	CI Target/Total
6252	2155G>A	G719S	5.11%	4.136% -- 6.298%
6225	p. 2236_2250del15	p. E746_A750del	4.51%	3.516% -- 5.787%
6241	p.2303G>T	p.S768I	4.41%	3.264% -- 5.949%
12376	2307_2308insGCCAGCGTG**	V769_D770insASV	by NGS	by NGS
6224	2573T>G	L858R	4.99%	3.926% -- 6.337%
6213	2582T>A	L861Q	5.63%	4.496% -- 7.037%
6493937	c.2389T>A	p.C797S/T790M	4.05%	2.921% -- 5.601%
43068	c.977G>A	p.C326Y	4.18%	3.15% -- 5.538%
12988	c.2125G>A	p.E709K	4.35%	3.217% -- 5.86%

Table1. Verification data of Quan-Plex™ EGFR ctDNA Panel. Mutation Allelic Frequency (MAF) was validated using digital PCR at 5%allelic frequency for 9 EGFR mutations.